Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma? Editorial
| Authors: | Maclachlan, K. H.; Lesokhin, A. M. |
| Title: | Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma? |
| Abstract: | Sklavenitis-Pistofidis et al. report clinical and correlative results of a single-arm phase II trial of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering myeloma. The authors explore the interactions between the genetics of the plasma cell clone and the immune microenvironment as potential biomarkers of treatment susceptibility and efficacy. © 2022 Elsevier Inc. |
| Keywords: | treatment response; genetics; lenalidomide; clinical feature; note; antineoplastic agent; multiple myeloma; antineoplastic combined chemotherapy protocols; dexamethasone; risk factor; high risk patient; risk; plasma cell; immune response; scoring system; natural killer cell; monocyte; plasma cells; tumor microenvironment; phase 2 clinical trial (topic); clinical outcome; smoldering multiple myeloma; dna sequencing; humans; human; elotuzumab |
| Journal Title: | Cancer Cell |
| Volume: | 40 |
| Issue: | 11 |
| ISSN: | 1535-6108 |
| Publisher: | Cell Press |
| Date Published: | 2022-11-14 |
| Start Page: | 1270 |
| End Page: | 1272 |
| Language: | English |
| DOI: | 10.1016/j.ccell.2022.10.014 |
| PUBMED: | 36379204 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Export Date: 1 December 2022 -- Source: Scopus |
